CARBAMAZEPINE DIHYDRATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H12N2O.2H2O
Molecular Weight	272.2991
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O.O.NC(=O)N1C2=CC=CC=C2C=CC3=CC=CC=C13

InChI

InChIKey=UPTJXAHTRRBMJE-UHFFFAOYSA-N

InChI=1S/C15H12N2O.2H2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17;;/h1-10H,(H2,16,18);2*1H2

HIDE SMILES / InChI

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/016608s097,018281s045,018927s038,020234s026lbl.pdf
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/carbamazepine.html http://www.rxlist.com/carnexiv-drug.htm http://www.wikidoc.org/index.php/Carbamazepine

Carbamazepine is an analgesic, anti-epileptic agent that is FDA approved for the treatment of epilepsy, trigeminal neuralgia. It appears to act by reducing polysynaptic responses and blocking the post-tetanic potentiation. It depresses thalamic potential and bulbar and polysynaptic reflexes, including the linguomandibular reflex in cats. Commonly reported side effects of carbamazepine include: dizziness, drowsiness, nausea, ataxia, and vomiting. Carbamazepine is a potent inducer of hepatic CYP1A2, 2B6, 2C9/19, and 3A4 and may reduce plasma concentrations of concomitant medications mainly metabolized by CYP1A2, 2B6, 2C9/19, and 3A4 through induction of their metabolism, like Boceprevir, Cyclophosphamide, Aripiprazole, Tacrolimus, Temsirolimus and others.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Sodium channel protein type 5 subunit alpha 9 Target ID: Q14524\|\|\|E9PFW7 Gene ID: 6331.0 Gene Symbol: SCN5A Target Organism: Homo sapiens (Human) Sources: http://www.drugbank.ca/drugs/DB00564 \| https://www.ncbi.nlm.nih.gov/pubmed/21480866 \| https://www.ncbi.nlm.nih.gov/pubmed/25688050	Blocker 537	152.0 µM [IC50]
Sodium channel protein type 2 subunit alpha 2 Target ID: Q99250 Gene ID: 6326.0 Gene Symbol: SCN2A Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/20526191 \| https://www.ncbi.nlm.nih.gov/pubmed/20643904 \| https://www.ncbi.nlm.nih.gov/pubmed/12391287	Blocker 537	25.0 µM [Ki]
Sodium channel protein type 3 subunit alpha 2 Target ID: Q9NY46\|\|\|Q9Y6P4 Gene ID: 6328.0 Gene Symbol: SCN3A Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/17381447	Blocker 537	16.0 µM [EC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Epilepsy 121 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/016608s097,018281s045,018927s038,020234s026lbl.pdf	Primary		Approved 8429	TEGRETOL Approved Use Epilepsy Carbamazepine is indicated for use as an anticonvulsant drug. Evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: 1. Partial seizures with complex symptomatology (psychomotor, temporal lobe). Patients with these seizures appear to show greater improvement than those with other types. 2. Generalized tonic-clonic seizures (grand mal). 3. Mixed seizure patterns which include the above, or other partial or generalized seizures. Absence seizures (petit mal) do not appear to be controlled by carbamazepine (see PRECAUTIONS, General). Trigeminal Neuralgia Carbamazepine is indicated in the treatment of the pain associated with true trigeminal neuralgia. Beneficial results have also been reported in glossopharyngeal neuralgia. This drug is not a simple analgesic and should not be used for the relief of trivial aches or pains. Launch Date 1968
Trigeminal neuralgia 9 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/016608s097,018281s045,018927s038,020234s026lbl.pdf	Primary		Approved 8429	TEGRETOL Approved Use Epilepsy Carbamazepine is indicated for use as an anticonvulsant drug. Evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: 1. Partial seizures with complex symptomatology (psychomotor, temporal lobe). Patients with these seizures appear to show greater improvement than those with other types. 2. Generalized tonic-clonic seizures (grand mal). 3. Mixed seizure patterns which include the above, or other partial or generalized seizures. Absence seizures (petit mal) do not appear to be controlled by carbamazepine (see PRECAUTIONS, General). Trigeminal Neuralgia Carbamazepine is indicated in the treatment of the pain associated with true trigeminal neuralgia. Beneficial results have also been reported in glossopharyngeal neuralgia. This drug is not a simple analgesic and should not be used for the relief of trivial aches or pains. Launch Date 1968

C_max

Value	Dose	Analyte	Population
3.2 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021710s11s012lbl.pdf	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	CARBAMAZEPINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: FASTED
1.9 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021710s11s012lbl.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	CARBAMAZEPINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
11 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021710s11s012lbl.pdf	800 mg 2 times / day multiple, oral dose: 800 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CARBAMAZEPINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
4.3 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021710s11s012lbl.pdf	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	CARBAMAZEPINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: HIGH-FAT
3.2 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021710s11s012lbl.pdf	1600 mg 1 times / day multiple, oral dose: 1600 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CARBAMAZEPINE-10,11-EPOXIDE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
1.5 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021710s11s012lbl.pdf	800 mg 1 times / day multiple, oral dose: 800 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CARBAMAZEPINE-10,11-EPOXIDE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
0.11 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021710s11s012lbl.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	CARBAMAZEPINE-10,11-EPOXIDE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
2.2 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021710s11s012lbl.pdf	800 mg 2 times / day multiple, oral dose: 800 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CARBAMAZEPINE-10,11-EPOXIDE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
32.6 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021710s11s012lbl.pdf	1600 mg 1 times / day multiple, oral dose: 1600 mg route of administration: Oral experiment type: MULTIPLE co-administered:		CARBAMAZEPINE-10,11-EPOXIDE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
15.7 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021710s11s012lbl.pdf	800 mg 1 times / day multiple, oral dose: 800 mg route of administration: Oral experiment type: MULTIPLE co-administered:		CARBAMAZEPINE-10,11-EPOXIDE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
37.5 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021710s11s012lbl.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	CARBAMAZEPINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
14.5 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021710s11s012lbl.pdf	800 mg 2 times / day multiple, oral dose: 800 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CARBAMAZEPINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
34 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021710s11s012lbl.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	CARBAMAZEPINE-10,11-EPOXIDE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
24% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021710s11s012lbl.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		CARBAMAZEPINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
50% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021710s11s012lbl.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		CARBAMAZEPINE-10,11-EPOXIDE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
1000 mg 2 times / day multiple, oral Highest studied dose Dose: 1000 mg, 2 times / day Route: oral Route: multiple Dose: 1000 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17561956 Page: p.1297	unhealthy, 73.1 ± 5.5 n = 91 Health Status: unhealthy Condition: Epilepsy Age Group: 73.1 ± 5.5 Sex: M+F Population Size: 91 Sources: https://pubmed.ncbi.nlm.nih.gov/17561956 Page: p.1297	Disc. AE: Skin and subcutaneous conditions NEC, Fatigue... AEs leading to discontinuation/dose reduction: Skin and subcutaneous conditions NEC (8.8%) Fatigue Somnolence Sources: https://pubmed.ncbi.nlm.nih.gov/17561956 Page: p.1297

AEs

AE	Significance	Dose	Population
Skin and subcutaneous conditions NEC	8.8% Disc. AE	1000 mg 2 times / day multiple, oral Highest studied dose Dose: 1000 mg, 2 times / day Route: oral Route: multiple Dose: 1000 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17561956 Page: p.1297	unhealthy, 73.1 ± 5.5 n = 91 Health Status: unhealthy Condition: Epilepsy Age Group: 73.1 ± 5.5 Sex: M+F Population Size: 91 Sources: https://pubmed.ncbi.nlm.nih.gov/17561956 Page: p.1297
Fatigue	Disc. AE	1000 mg 2 times / day multiple, oral Highest studied dose Dose: 1000 mg, 2 times / day Route: oral Route: multiple Dose: 1000 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17561956 Page: p.1297	unhealthy, 73.1 ± 5.5 n = 91 Health Status: unhealthy Condition: Epilepsy Age Group: 73.1 ± 5.5 Sex: M+F Population Size: 91 Sources: https://pubmed.ncbi.nlm.nih.gov/17561956 Page: p.1297
Somnolence	Disc. AE	1000 mg 2 times / day multiple, oral Highest studied dose Dose: 1000 mg, 2 times / day Route: oral Route: multiple Dose: 1000 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17561956 Page: p.1297	unhealthy, 73.1 ± 5.5 n = 91 Health Status: unhealthy Condition: Epilepsy Age Group: 73.1 ± 5.5 Sex: M+F Population Size: 91 Sources: https://pubmed.ncbi.nlm.nih.gov/17561956 Page: p.1297

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737 inducer 781			inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	CYP2B6 664 UGT2B7 389 UGT1A1 418 UGT1A3 422 UGT1A6 307 UGT1A9 380 UGT2B4 249 UGT1A4 347	CYP1A2 701 CYP2B6 547 UGT1A6 34 UGT1A7 2

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP3A4 1925	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/016608s115_018281_s058_018927s055_020234_s047.pdf@page=10 Page: 12.0	strong	yes (co-administration study) Comment: Midazolam plasma concentrations reduced dramatically in patients treated with carbamazepine and phenytoin; The CYP3A4-mediated metabolism of cyclosporin is markedly accelerated by carbamazepine comedication; Many other likely DDIs with carbamazepine. See https://pubmed.ncbi.nlm.nih.gov/8877250/ Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/016608s115_018281_s058_018927s055_020234_s047.pdf@page=10 Page: 12.0
CYP1A2 1692	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020712s036lbl.pdf#page=12 Page: 12.0	yes
CYP2B6 1001	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/016608s115_018281_s058_018927s055_020234_s047.pdf@page=10 Page: 10.0	yes
UGT1A6 141	inducer 1573 Sources: https://pubmed.ncbi.nlm.nih.gov/29158009/	yes
UGT1A7 23	inducer 1573 Sources: https://pubmed.ncbi.nlm.nih.gov/29158009/	yes

Drug as victim

Target	Modality	Activity	Clinical evidence
UGT1A1 418	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/15292462/	no
UGT1A3 422	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/15292462/	no
UGT1A4 347	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/15292462/	no
UGT1A6 307	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/15292462/	no
UGT1A9 380	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/15292462/	no
UGT2B4 249	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/15292462/	no
CYP2B6 664	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/12386121/	yes
UGT2B7 389	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/15292462/	yes
CYP3A4 1737	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020712s036lbl.pdf#page=12; https://pubmed.ncbi.nlm.nih.gov/8877250/ Page: 12.0	yes	yes (co-administration study) Comment: A 2- to 4-fold increase in serum carbamazepine concentrations has been reported in patients given troleandomycin or erythromycin (CYP3A4 inhibitors); Many other likely DDIs with carbamazepine. See https://pubmed.ncbi.nlm.nih.gov/8877250/ Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020712s036lbl.pdf#page=12; https://pubmed.ncbi.nlm.nih.gov/8877250/ Page: 12.0

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://pubmed.ncbi.nlm.nih.gov/17584909/ Page: 6.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:3387	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3387
ChemicalBook	CB1143564	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB1143564
MolPort	MolPort-000-710-574	https://www.molport.com/shop/molecule-link/MolPort-000-710-574
MolPort	MolPort-023-220-275	https://www.molport.com/shop/molecule-link/MolPort-023-220-275
Selleck Chemicals	Carbamazepine(Carbatrol)	http://www.selleckchem.com/products/Carbamazepine(Carbatrol).html
ZINC	ZINC000000004785	http://zinc15.docking.org/substances/ZINC000000004785
eMolecules	27677745	https://www.emolecules.com/cgi-bin/more?vid=27677745
eMolecules	535714	https://www.emolecules.com/cgi-bin/more?vid=535714

PubMed

Title	Date	PubMed
A common mutation in the methylenetetrahydrofolate reductase gene is a determinant of hyperhomocysteinemia in epileptic patients receiving anticonvulsants.	1999 Aug	10459572
Effects of the calcium antagonists verapamil and nitrendipine on carbamazepine withdrawal.	1999 Dec	10702963
[Carbamazepine induced hyponatremia].	1999 Jan	10024990
Potential fluconazole-induced carbamazepine toxicity.	1999 Jul-Aug	10466905
A reporter gene assay to assess the molecular mechanisms of xenobiotic-dependent induction of the human CYP3A4 gene in vitro.	1999 Mar	10219967
Carbamazepine-induced hepatorenal failure in a child.	1999 May	10331832
Epileptic negative myoclonus induced by carbamazepine in a child with BECTS. Benign childhood epilepsy with centrotemporal spikes.	1999 Sep	10513696
Carbamazepine-associated severe left ventricular dysfunction.	2000	10866337
Worsening of symptoms of multiple sclerosis associated with carbamazepine.	2000 Apr 22	10775221
Sodium valproate inhibits production of TNF-alpha and IL-6 and activation of NF-kappaB.	2000 Feb 28	10700573
Phenytoin poisoning after using Chinese proprietary medicines.	2000 Jul	11002387
Potential interaction between ritonavir and carbamazepine.	2000 Jul	10907977
Block of rat brain recombinant SK channels by tricyclic antidepressants and related compounds.	2000 Jul 28	10915830
[A case of superior sagittal sinus thrombosis following long-term medication with carbamazepine].	2000 Jun	11086405
Color vision in epilepsy patients treated with vigabatrin or carbamazepine monotherapy.	2000 May	10811079
[Carbamazepine-induced hepatitis].	2000 Oct 10	11143408
Novel treatments for bipolar disorder.	2001 Apr	11281816
Comparison the cognitive effect of anti-epileptic drugs in seizure-free children with epilepsy before and after drug withdrawal.	2001 Apr	11255074
Illness characteristics and their association with prescription patterns for bipolar I disorder.	2001 Feb	11256463
Antiepileptic drug withdrawal in patients with temporal lobe epilepsy undergoing presurgical video-EEG monitoring.	2001 Feb	11240598
The influence of food on the bioavailability of a twice-daily controlled release carbamazepine formulation.	2001 Feb	11210399
Rufinamide: a double-blind, placebo-controlled proof of principle trial in patients with epilepsy.	2001 Feb	11164700
The response of neuropathic pain and pain in complex regional pain syndrome I to carbamazepine and sustained-release morphine in patients pretreated with spinal cord stimulation: a double-blinded randomized study.	2001 Feb	11159256
Independent short-term variability of spike-like (600 Hz) and postsynaptic (N20) cerebral SEP components.	2001 Feb 12	11209948
A model of atypical absence seizures: EEG, pharmacology, and developmental characterization.	2001 Feb 13	11171899
[Maintenance dose requirement for phenytoin is lowered in genetically impaired drug metabolism independent of concommitant use of other antiepileptics].	2001 Feb 17	11234294
Determination of drug residues in water by the combination of liquid chromatography or capillary electrophoresis with electrospray mass spectrometry.	2001 Feb 23	11263577
[Carbamazepine-induced SIADH with clinical signs of delirium].	2001 Jan	11236337
Relief of cluster headache and cranial neuralgias. Promising prophylactic and symptomatic treatments.	2001 Jan	11198259
Ritonavir-induced carbamazepine toxicity.	2001 Jan	11197575
Acute intermittent porphyria, seizures, and antiepileptic drugs: a report on a 3-year-old Nigerian boy.	2001 Jan	11181101
Effects of antiepileptic drugs on rat platelet aggregation: ex vivo and in vitro study.	2001 Jan	11137387
[Klüver-Bucy syndrome in herpetic meningoencephalitis].	2001 Jan 27	11225480
Mood stabilizers and ion regulation.	2001 Jan-Feb	11159930
Taking the sting out of trigeminal neuralgia.	2001 Mar	11288566
Influence of retigabine on the anticonvulsant activity of some antiepileptic drugs against audiogenic seizures in DBA/2 mice.	2001 Mar	11284448
Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms.	2001 Mar	11255328
Carbamazepine prevents imipramine-induced behavioural sensitization to the dopamine D(2)-like receptor agonist quinpirole.	2001 Mar 23	11282119

Patents

Sample Use Guides

In Vivo Use Guide

Initial Dose: 400 mg per day. Subsequent Dose: add up to 200 mg per day at weekly intervals. Maximum daily dose is 1600 mg

Route of Administration: Other

In Vitro Use Guide

Human liver microsomes (HLMs) converted carbamazepine (30-300 microM) to 3-hydroxycarbamazepine at rates >25 times those of 2-hydroxycarbamazepine. Rates of carbamazepine 2- and 3-hydroxylation correlated strongly with CYP2B6 activity (r >or= 0.757) in a panel of HLMs (n = 8). Carbamazepine 3-hydroxylation also correlated significantly with CYP2C8 activity at a carbamazepine concentration of 30 microM.

Name

Type

Language

CARBAMAZEPINE DIHYDRATE

Common Name

English

5H-DIBENZ(B,F)AZEPINE-5-CARBOXAMIDE, HYDRATE (1:2)

Systematic Name

English

Code System Code Type Description

PUBCHEM

158856

Created by admin on Fri Dec 15 19:17:47 GMT 2023 , Edited by admin on Fri Dec 15 19:17:47 GMT 2023

PRIMARY

CAS

85756-57-6

Created by admin on Fri Dec 15 19:17:47 GMT 2023 , Edited by admin on Fri Dec 15 19:17:47 GMT 2023

PRIMARY

EPA CompTox

DTXSID00235052

Created by admin on Fri Dec 15 19:17:47 GMT 2023 , Edited by admin on Fri Dec 15 19:17:47 GMT 2023

PRIMARY

FDA UNII

78M1RMW7Q8

Created by admin on Fri Dec 15 19:17:47 GMT 2023 , Edited by admin on Fri Dec 15 19:17:47 GMT 2023

PRIMARY

PARENT (SALT/SOLVATE)


					33CM23913M

CARBAMAZEPINE

SUBSTANCE RECORD


					78M1RMW7Q8

CARBAMAZEPINE DIHYDRATE

Details

SMILES

InChI

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

Cmax

AUC

T1/2

Funbound

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Tox targets

Sourcing

PubMed

Patents

Sample Use Guides

C_max

T_1/2

F_unbound

Drug as perpetrator